PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO EVALUATE THE SYSTEMIC EXPOSURE OF GEFITINIB IN THE CYP2D6 ULTRARAPID METABOLIZERS AND EXTENSIVE METABOLIZERS.

被引：0
|
作者：
Chen, Y. [1 ]
Zhou, W. [1 ]
Tang, W. [1 ]
Zhou, D. [1 ]
Masson, E. [1 ]
机构：
[1] Astrazeneca, Waltham, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-021
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [11] CHLORPHENIRAMINE PLASMA ANTAGONIST ACTIVITY IN POOR AND EXTENSIVE METABOLIZERS OF CYP2D6
    YASUDA, SU
    BARBEY, JT
    HEWETT, J
    WOOSLEY, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 170 - 170
  • [12] Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects
    Damy, T
    Pousset, F
    Caplain, H
    Hulot, JS
    Lechat, P
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (01) : 113 - 123
  • [13] POOR METABOLIZERS OF NICOTINE AND CYP2D6 POLYMORPHISM
    CHOLERTON, S
    ARPANAHI, A
    MCCRACKEN, N
    BOUSTEAD, C
    TABER, H
    JOHNSTONE, E
    LEATHART, J
    DALY, AK
    IDLE, JR
    LANCET, 1994, 343 (8888): : 62 - 63
  • [14] Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene
    Lovlie, R
    Daly, AK
    Molven, A
    Idle, JR
    Steen, VM
    FEBS LETTERS, 1996, 392 (01) : 30 - 34
  • [15] Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers
    Li, Susie Xiujiang
    Pequignot, Edward
    Panebianco, Deborah
    Lupinacci, Paul
    Majumdar, Anup
    Rosen, Laura
    Ahmed, Tuli
    Royalty, Lane E.
    Rushmore, Thomas H.
    Murphy, M. Gail
    Petty, Kevin J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (07): : 792 - 801
  • [16] Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers
    DeVane, CL
    Markowitz, JS
    Carson, SW
    Boulton, DW
    Gill, HS
    Nahas, Z
    Risch, SC
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (03) : 347 - 349
  • [17] Modelling the pharmacokinetics of tramadol: On the difference between CYP2D6 extensive and poor metabolizers
    Di Patti, F.
    Fanelli, D.
    Pedersen, R. S.
    Giuliani, C.
    Torricelli, F.
    JOURNAL OF THEORETICAL BIOLOGY, 2008, 254 (03) : 568 - 574
  • [18] Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6
    Dilger, K
    Greiner, B
    Fromm, MF
    Hofmann, U
    Kroemer, HK
    Eichelbaum, M
    PHARMACOGENETICS, 1999, 9 (05): : 551 - 559
  • [19] Pharmacokinetics of Oxycodone in Extensive and Poor Metabolizers of CYP2D6 during Cotreatment with Placebo or Quinidine
    Sirhan-Daneau, Andrea
    Michaud, Veronique
    St-Onge, Maude
    Turgeon, Jacques
    DRUG METABOLISM REVIEWS, 2009, 41 : 81 - 82
  • [20] Gender differences and intrasubject variability in CYP2D6 activity in extensive metabolizers of dextromethorphan (DM).
    Decker, J
    Lindley, C
    Williamson, K
    McCune, J
    Graff, D
    Carson, S
    Pieper, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 215 - 215
12345